, 1998 En esta memoria se describe un estudio del empleo de compuestos organolíticos alfa-halogenados en la síntesis de compuestos enantioméricamente puros. En el primer capítulo se recoge un método que permite obtener alfa-hidroxi- o alfa-aminocetonas, con uno
Baragaña Ruibal, Beatriz
core
Advanced Blood-Brain Barrier Drug Delivery. [PDF]
Pharmaceutics, 2022 Pardridge WM.
europepmc +1 more source
Antibody-Based Biologics for CNS Disorders. [PDF]
Antibodies (Basel)Hui EK, Boado RJ.
europepmc +1 more source
Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid. [PDF]
Metab Brain Dis, 2022 Sato Y +5 more
europepmc +1 more source
IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport. [PDF]
Pharmaceutics, 2022 Boado RJ.
europepmc +1 more source
Identificazione e caratterizzazione biochimicadell'interazione alfa-sinucleina-alfa-trombina
, 2012 Valutazione dell'interazione tra alfa-sinucleina, proteine coinvolte nei disturbi neurodegenerativi e alfa-trombina, enzima chiave nei processi ...
Pagliara, Federico
core
Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening. [PDF]
Int J Neonatal ScreenUeda Y +11 more
europepmc +1 more source
Mucopolysaccharidoses and the blood-brain barrier. [PDF]
Fluids Barriers CNS, 2022 Sahin O +4 more
europepmc +1 more source
Advances in Therapies for Mucopolysaccharidoses. [PDF]
Curr Issues Mol BiolSzmydtka J +12 more
europepmc +1 more source
Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme. [PDF]
Mol Genet Metab Rep, 2022 Hahn A +7 more
europepmc +1 more source